Original Research21 April 2015
A Retrospective Cohort Study
    Author, Article and Disclosure Information
    Background:

    Prediabetes affects 1 in 3 Americans. Both intensive lifestyle intervention and metformin can prevent or delay progression to diabetes. Over the past decade, lifestyle interventions have been translated across various settings, but little is known about the translation of evidence surrounding metformin use.

    Objective:

    To examine metformin prescription for diabetes prevention and patient characteristics that may affect metformin prescription.

    Design:

    Retrospective cohort analysis over a 3-year period.

    Setting:

    Employer groups that purchased health plans from the nation's largest private insurer.

    Participants:

    A national sample of 17 352 working-age adults with prediabetes insured for 3 continuous years between 2010 and 2012.

    Measurements:

    Percentage of health plan enrollees with prediabetes who were prescribed metformin.

    Results:

    Only 3.7% of patients with prediabetes were prescribed metformin over the 3-year study window. After adjustment for age, income, and education, the predicted probability of metformin prescription was almost 2 times higher among women and obese patients and more than 1.5 times higher among patients with 2 or more comorbid conditions.

    Limitation:

    Missing data on lifestyle interventions, possible misclassification of prediabetes and metformin use, and inability to define eligible patients exactly as defined in the American Diabetes Association guidelines.

    Conclusion:

    Evidence shows that metformin is rarely prescribed for diabetes prevention in working-age adults. Future studies are needed to understand potential barriers to wider adoption of this safe, tolerable, evidence-based, and cost-effective prediabetes therapy.

    Primary Funding Source:

    Centers for Disease Control and Prevention (Division of Diabetes Translation) and the National Institute of Diabetes and Digestive and Kidney Diseases.

    References

    • 1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: Centers for Disease Control and Prevention; 2011. Accessed at www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf on 19 February 2015. Google Scholar
    • 2. Centers for Disease Control and Prevention. Prediabetes: Could It Be You? Atlanta, GA: Centers for Disease Control and Prevention; 2014. Accessed at www.cdc.gov/diabetes/pubs/statsreport14/prediabetes-infographic.pdf on 4 February 2015. Google Scholar
    • 3. Knowler WC Barrett-Connor E Fowler SE Hamman RF Lachin JM Walker EA et alDiabetes Prevention Program Research GroupReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med2002;346:393-403. [PMID: 11832527] CrossrefMedlineGoogle Scholar
    • 4. Lindström J Louheranta A Mannelin M Rastas M Salminen V Eriksson J et alFinnish Diabetes Prevention Study GroupThe Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care2003;26:3230-6. [PMID: 14633807] CrossrefMedlineGoogle Scholar
    • 5. Lindström J Ilanne-Parikka P Peltonen M Aunola S Eriksson JG Hemiö K et alFinnish Diabetes Prevention Study GroupSustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673-9. [PMID: 17098085] CrossrefMedlineGoogle Scholar
    • 6. Ramachandran A Snehalatha C Mary S Mukesh B Bhaskar AD Vijay V Indian Diabetes Prevention Programme (IDPP)The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia2006;49:289-97. [PMID: 16391903] CrossrefMedlineGoogle Scholar
    • 7. Li G Zhang P Wang J Gregg EW Yang W Gong Q et alThe long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet2008;371:1783-9. [PMID: 18502303] doi:10.1016/S0140-6736(08)60766-7 CrossrefMedlineGoogle Scholar
    • 8. Knowler WC Fowler SE Hamman RF Christophi CA Hoffman HJ Brenneman AT et alDiabetes Prevention Program Research Group10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374:1677-86. [PMID: 19878986] doi:10.1016/S0140-6736(09)61457-4 CrossrefMedlineGoogle Scholar
    • 9. Ali MK Echouffo-Tcheugui J Williamson DF How effective were lifestyle interventions in real-world settings that were modeled on the Diabetes Prevention Program? Health Aff (Millwood)2012;31:67-75. [PMID: 22232096] doi:10.1377/hlthaff.2011.1009 CrossrefMedlineGoogle Scholar
    • 10. Cardona-Morrell M Rychetnik L Morrell SL Espinel PT Bauman A Reduction of diabetes risk in routine clinical practice: are physical activity and nutrition interventions feasible and are the outcomes from reference trials replicable? A systematic review and meta-analysis. BMC Public Health2010;10:653. [PMID: 21029469] doi:10.1186/1471-2458-10-653 CrossrefMedlineGoogle Scholar
    • 11. Dunkley AJ Bodicoat DH Greaves CJ Russell C Yates T Davies MJ et alDiabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis. Diabetes Care2014;37:922-33. [PMID: 24652723] doi:10.2337/dc13-2195 CrossrefMedlineGoogle Scholar
    • 12. Kahn R Davidson MB The reality of type 2 diabetes prevention. Diabetes Care2014;37:943-9. [PMID: 24652724] doi:10.2337/dc13-1954 CrossrefMedlineGoogle Scholar
    • 13. American Diabetes AssociationStandards of medical care in diabetes—2014. Diabetes Care2014;37 Suppl 1:S14-80. [PMID: 24357209] doi:10.2337/dc14-S014 CrossrefMedlineGoogle Scholar
    • 14. Diabetes Prevention Program Research GroupLong-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35:731-7. [PMID: 22442396] doi:10.2337/dc11-1299 CrossrefMedlineGoogle Scholar
    • 15. Schmittdiel JA Adams SR Segal J Griffin MR Roumie CL Ohnsorg K et alNovel use and utility of integrated electronic health records to assess rates of prediabetes recognition and treatment: brief report from an integrated electronic health records pilot study. Diabetes Care2014;37:565-8. [PMID: 24271190] doi:10.2337/dc13-1223 CrossrefMedlineGoogle Scholar
    • 16. American Diabetes AssociationStandards of medical care in diabetes—2008. Diabetes Care2008;31 Suppl 1:S12-54. [PMID: 18165335] doi:10.2337/dc08-S012 CrossrefMedlineGoogle Scholar
    • 17. Heilbrunn E. Top Health Insurance Companies. New York: U.S. News & World Report; 2013. Accessed at http://health.usnews.com/health-news/health-insurance/articles/2013/12/16/top-health-insurance-companies on 28 December 2013. Google Scholar
    • 18. Duru OK Mangione CM Chan C Keckhafer A Kimbro L Kirvan KA et alEvaluation of the Diabetes Health Plan to improve diabetes care and prevention. Prev Chronic Dis2013;10:E16. [PMID: 23369769] doi:10.5888/pcd10.120150 CrossrefMedlineGoogle Scholar
    • 19. Xiao J Chen S Zhang C Chang S The effectiveness of metformin ovulation induction treatment in patients with PCOS: a systematic review and meta-analysis. Gynecol Endocrinol2012;28:956-60. [PMID: 22808990] doi:10.3109/09513590.2012.705368 CrossrefMedlineGoogle Scholar
    • 20. Baran S Api M Goksedef BP Cetin A Comparison of metformin and clomiphene citrate therapy for induction of ovulation in the polycystic ovary syndrome. Arch Gynecol Obstet2010;282:439-43. [PMID: 20473763] doi:10.1007/s00404-010-1497-y CrossrefMedlineGoogle Scholar
    • 21. Mathur R Alexander CJ Yano J Trivax B Azziz R Use of metformin in polycystic ovary syndrome. Am J Obstet Gynecol2008;199:596-609. [PMID: 19084097] doi:10.1016/j.ajog.2008.09.010 CrossrefMedlineGoogle Scholar
    • 22. White IR Royston P Wood AM Multiple imputation using chained equations: issues and guidance for practice. Stat Med2011;30:377-99. [PMID: 21225900] doi:10.1002/sim.4067 CrossrefMedlineGoogle Scholar
    • 23. Rubin DB Multiple imputation after 18+ years. J Am Stat Assoc1996;91:473-89. doi:10.1080/01621459.1996.10476908 CrossrefGoogle Scholar
    • 24. Crandall J Schade D Ma Y Fujimoto WY Barrett-Connor E Fowler S et alDiabetes Prevention Program Research GroupThe influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci2006;61:1075-81. [PMID: 17077202] CrossrefMedlineGoogle Scholar
    • 25. Diabetes Prevention Program Research GroupThe 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care2012;35:723-30. [PMID: 22442395] doi:10.2337/dc11-1468 CrossrefMedlineGoogle Scholar
    • 26. Ramachandran A Snehalatha C Yamuna A Mary S Ping Z Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548-52. [PMID: 17670917] CrossrefMedlineGoogle Scholar
    • 27. Fradkin JE Roberts BT Rodgers GP What's preventing us from preventing type 2 diabetes? N Engl J Med2012;367:1177-9. [PMID: 23013070] CrossrefMedlineGoogle Scholar
    • 28. Nichols GA Hillier TA Brown JB Progression from newly acquired impaired fasting glucose to type 2 diabetes. Diabetes Care2007;30:228-33. [PMID: 17259486] CrossrefMedlineGoogle Scholar
    • 29. Lenfant C Shattuck lecture—clinical research to clinical practice—lost in translation? N Engl J Med2003;349:868-74. [PMID: 12944573] CrossrefMedlineGoogle Scholar
    • 30. Nathan DM Davidson MB DeFronzo RA Heine RJ Henry RR Pratley R et alAmerican Diabetes AssociationImpaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care2007;30:753-9. [PMID: 17327355] CrossrefMedlineGoogle Scholar